Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $395.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target boosted by Wells Fargo & Company from $333.00 to $395.00 in a research report sent to investors on Friday,Benzinga reports. They currently have an equal weight rating on the biopharmaceutical company’s stock.

ALNY has been the topic of a number of other research reports. Morgan Stanley boosted their target price on shares of Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the company an “equal weight” rating in a research report on Friday. Piper Sandler upped their price objective on shares of Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the stock an “overweight” rating in a report on Friday. Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, July 5th. BMO Capital Markets upped their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the stock an “outperform” rating in a report on Tuesday, June 24th. Finally, UBS Group upped their price objective on shares of Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the stock a “buy” rating in a report on Friday, May 2nd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and twenty-three have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $392.13.

Alnylam Pharmaceuticals Stock Up 2.4%

Alnylam Pharmaceuticals stock opened at $401.80 on Friday. The company has a quick ratio of 2.98, a current ratio of 3.04 and a debt-to-equity ratio of 8.88. Alnylam Pharmaceuticals has a 12-month low of $205.87 and a 12-month high of $402.43. The firm’s fifty day moving average is $318.24 and its 200 day moving average is $279.01. The company has a market capitalization of $52.67 billion, a PE ratio of -162.67 and a beta of 0.25.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 444.38%. The company had revenue of $594.19 million for the quarter, compared to analyst estimates of $584.32 million. During the same quarter in the previous year, the firm earned ($0.16) EPS. The firm’s revenue was up 20.2% on a year-over-year basis. As a group, sell-side analysts predict that Alnylam Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Yvonne Greenstreet sold 31,640 shares of the stock in a transaction dated Friday, May 30th. The shares were sold at an average price of $304.39, for a total transaction of $9,630,899.60. Following the completion of the transaction, the chief executive officer owned 48,948 shares in the company, valued at approximately $14,899,281.72. This represents a 39.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Capital World Investors boosted its position in Alnylam Pharmaceuticals by 0.6% during the fourth quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company’s stock worth $3,906,284,000 after purchasing an additional 92,101 shares during the period. Vanguard Group Inc. boosted its position in Alnylam Pharmaceuticals by 2.5% during the first quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company’s stock worth $3,525,544,000 after purchasing an additional 323,206 shares during the period. Capital Research Global Investors boosted its position in Alnylam Pharmaceuticals by 32.9% during the fourth quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company’s stock worth $1,639,767,000 after purchasing an additional 1,724,610 shares during the period. T. Rowe Price Investment Management Inc. boosted its position in Alnylam Pharmaceuticals by 0.8% during the first quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company’s stock worth $1,192,988,000 after purchasing an additional 33,696 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of Alnylam Pharmaceuticals by 5.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company’s stock worth $946,466,000 after buying an additional 185,783 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.